Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metamizole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.77 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metamizole SCHEMBL24996 | 0.87 | ALOX15 (1.00) | ALOX15KDM4EMAPTALOX12PTGS1 | |
| Metamizole SCHEMBL1825291 | 0.86 | ALOX15 (0.97) | ALOX15KDM4EMAPTALOX12PTGS1 | |
| Metamizole SCHEMBL24995 | 0.86 | ALOX15 (0.97) | ALOX15KDM4EMAPTALOX12PTGS1 | |
| Metamizole SCHEMBL28278546 | 0.85 | ALOX15 (0.95) | ALOX15KDM4EMAPTALOX12PTGS1 | |
| Metamizole SCHEMBL17331306 | 0.84 | ALOX15 (0.83) | ALOX15KDM4EMAPTALOX12PTGS1 | |
| Metamizole SCHEMBL24997 | 0.77 | PTGS1 (1.00) | ALOX15KDM4EMAPTALOX12PTGS1 | |
| Metamizole SCHEMBL27828487 | 0.76 | PTGS1 (0.97) | ALOX15KDM4EMAPTALOX12PTGS1 | |
| Metamizole SCHEMBL27598082 | 0.76 | PTGS1 (0.97) | ALOX15KDM4EMAPTALOX12PTGS1 | |
| SCHEMBL27870014 | 0.76 | PTGS1 (0.75) | ALOX15KDM4EMAPTALOX12PTGS1 | |
| Metamizole SCHEMBL867884 | 0.76 | PTGS1 (0.97) | ALOX15KDM4EMAPTALOX12PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023049265-A1 | P-SELECTIN INHIBITORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20220195524-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND MANAGEMENT OF NEURODEGERATIVE DISEASES | UNIV SOUTH FLORIDA (US) | 2022-06-23 | — | — | US | disclosed |
| US-11214835-B1 | Methods and compositions for diagnosis and management of neurodegerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210277368-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CHEMICAL WARFARE AGENTS | BATTELLE MEMORIAL INSTITUTE (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3079691-B1 | PHARMACEUTICAL COMPOSITION COMPRISING DANTROLENE AS RYANODINE RECEPTOR ANTAGONIST FOR FACILITATING WOUND HEALING | UNIV SZEGEDI (HU) | 2020-07-01 | — | — | EP | disclosed |
| US-9757360-B2 | Pharmaceutical composition comprising a ryanodine receptor antagonist for facilitating wound healing | Szegedi Tudományegyetem (HU) | 2017-09-12 | — | — | US | disclosed |
| US-9649292-B2 | Method for treating prostate cancer and/or gastrointestinal cancer | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2017-05-16 | — | — | US | disclosed |
| US-20170100365-A1 | METHOD FOR TREATING PROSTATE CANCER AND/OR GASTROINTESTINAL CANCER | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2017-04-13 | — | — | US | disclosed |
| US-9617388-B2 | Process for making a polyzwitterion or polyzwitterionic acid | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2017-04-11 | — | — | US | disclosed |
| US-9580521-B1 | Process for making a poly(zwitterion/dianion) | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2017-02-28 | — | — | US | disclosed |
| US-20100286251-A1 | Mammalian Genes Involved In Viral Infection And Tumor Suppression | RUBIN DONALD H | 2010-11-11 | — | — | US | disclosed |
| US-7691599-B2 | Mammalian genes involved in viral infection and tumor suppression | Zirus, Inc. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100003712-A1 | BIOMARKER FOR ASSESSING RESPONSE TO CHYMASE TREATMENT | ZHANG ZHIMING | 2010-01-07 | — | — | US | disclosed |
| WO-2009148958-A1 | BIOMARKER FOR ASSESSING RESPONSE TO CHYMASE TREATMENT | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-10 | — | — | WO | disclosed |
| US-20090118358-A1 | Kainate Receptor-Selective Epimeric Analogs of Dysiherbaine | NORTHWESTERN UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| EP-1572084-A4 | MAMMALIAN GENES INVOLVED IN VIRAL INFECTION AND TUMOR SUPPRESSION | UNIV VANDERBILT (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070254329-A1 | Screening a compound for effectiveness in treating a viral infection, a cellular gene functionally encoding a gene product whose overexpression inhibits reproduction of the virus but does not prevent survival of the cell; detecting the level of the gene product produced | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| US-20060142395-A1 | Modulation of intracellular calcium signaling by N-acylethanolamines | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2006-06-29 | — | — | US | disclosed |
| EP-1572084-A2 | MAMMALIAN GENES INVOLVED IN VIRAL INFECTION AND TUMOR SUPPRESSION | Vanderbilt University (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004010925-A2 | MAMMALIAN GENES INVOLVED IN VIRAL INFECTION AND TUMOR SUPPRESSION | VANDERBILT UNIVERSITY (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118358-A1 | Kainate Receptor-Selective Epimeric Analogs of Dysiherbaine | GRIK5, GRIK4, GRM5 | PTGS1 2797/4885ALOX15 2580/4885KDM4E 1740/4885 |
| US-11214835-B1 | Methods and compositions for diagnosis and management of neurodegerative diseases | PSEN2, CLN6, PSEN1 | PTGS1 2301/4885ALOX15 550/4885KDM4E 1670/4885 |
| US-20170100365-A1 | METHOD FOR TREATING PROSTATE CANCER AND/OR GASTROINTESTINAL CANCER | CASP3, BAD, KLK3 | PTGS1 870/4885ALOX15 2642/4885KDM4E 4060/4885 |
| US-20060142395-A1 | Modulation of intracellular calcium signaling by N-acylethanolamines | NCS1, ITPR2, CACNA1B | PTGS1 2311/4885ALOX15 1789/4885KDM4E 2287/4885 |
| US-20220195524-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND MANAGEMENT OF NEURODEGERATIVE DISEASES | PSEN2, CLN6, PSEN1 | PTGS1 2301/4885ALOX15 550/4885KDM4E 1670/4885 |
| US-20100003712-A1 | BIOMARKER FOR ASSESSING RESPONSE TO CHYMASE TREATMENT | CMA1, CPA3, SERPINB1 | PTGS1 1557/4885ALOX15 2684/4885KDM4E 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.